Cargando…

Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells

Recently, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized non-small cell lung cancer (NSCLC) treatment. However, resistance remains a major obstacle. Anexelekto (AXL) is a member of receptor tyrosine kinases (RTKs) and shares the same downstream signaling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Yaqiong, Zhang, Zengli, Miao, Liyun, Yang, Zhimin, Yang, Jie, Wang, Yinhua, Qian, Danwen, Cai, Hourong, Wang, Yongsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838623/ https://www.ncbi.nlm.nih.gov/pubmed/27712586 http://dx.doi.org/10.3727/096504016X14648701447814

Ejemplares similares

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
por: Wang, Xiaomeng, et al.
Publicado: (2019)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression
por: Safaric Tepes, Polona, et al.
Publicado: (2021)

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
por: Kim, Donghwa, et al.
Publicado: (2019)

Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling
por: Wang, Wei, et al.
Publicado: (2021)

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
por: Sun, Qi, et al.
Publicado: (2022)

NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR–TKI Resistance in Lung Adenocarcinoma
por: Zhang, Youwei, et al.
Publicado: (2019)

Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells
por: Miao, Liyun, et al.
Publicado: (2016)

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
por: Fang, Wenfeng, et al.
Publicado: (2020)

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer
por: Zhang, Zhimin, et al.
Publicado: (2020)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
por: Long, Jianlin, et al.
Publicado: (2022)

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer
por: Wang, Tong-Hong, et al.
Publicado: (2020)

Primary resistance to EGFR inhibition in glioblastoma is mediated by a TNF-JNK-Axl-ERK signaling axis
por: Guo, Gao, et al.
Publicado: (2017)

Tumor-associated macrophage-derived exosomes promote EGFR-TKI resistance in non-small cell lung cancer by regulating the AKT, ERK1/2 and STAT3 signaling pathways
por: Yuan, Shiyang, et al.
Publicado: (2022)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer
por: Du, Wenwen, et al.
Publicado: (2020)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway
por: Wang, Lihui, et al.
Publicado: (2018)

Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer
por: Wang, Haocheng, et al.
Publicado: (2020)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Collagen type I induces EGFR‐TKI resistance in EGFR‐mutated cancer cells by mTOR activation through Akt‐independent pathway
por: Yamazaki, Shota, et al.
Publicado: (2018)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Terp, Mikkel G., et al.
Publicado: (2021)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma
por: Chen, Hongjin, et al.
Publicado: (2021)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
por: Chen, Yi, et al.
Publicado: (2023)

Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca(2+) overload-induced ferroptosis
por: Ni, Yinyun, et al.
Publicado: (2023)

Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report
por: Wang, Lingfei, et al.
Publicado: (2020)

Morphine promotes microglial activation by upregulating the EGFR/ERK signaling pathway
por: Yang, Yaqiong, et al.
Publicado: (2021)

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
por: Yufen, Xu, et al.
Publicado: (2016)

Targeting TF-AKT/ERK-EGFR Pathway Suppresses the Growth of Hepatocellular Carcinoma
por: Huang, Shan-Zhou, et al.
Publicado: (2019)

Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells
por: Wang, Jun, et al.
Publicado: (2022)

Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study
por: Wang, Xia, et al.
Publicado: (2021)

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
por: Yan, Dan, et al.
Publicado: (2021)

EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
por: Wu, Jing-Xun, et al.
Publicado: (2018)

LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt-NF-κB activation
por: Liu, Siwen, et al.
Publicado: (2018)

Construction of the model for predicting prognosis by key genes regulating EGFR-TKI resistance
por: Zhuge, Jinke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ikq2rotleptfqa3ebhtrbmalpt